Abstract:Acute myeloid leukaemia (AML) is a haematological malignancy characterized by the uncontrolled proliferation of haematopoietic stem/progenitor cells. The effectiveness of chemotherapy in the treatment of AML is limited by drug resistance and relapse because the bone marrow microenvironment protects AML cells against chemotherapeutic drugs (Meads et al, 2008). The bone marrow stromal cells (BMSCs) secrete SDF-1⍺ (also termed CXCL12), which can activate C-X-C chemokine receptor type 4 (CXCR4) on the surface of AML cells to facilitate the trafficking and retention of AML cells in the bone marrow and promote their growth and anti-apoptotic responses (Burger & Burkle, 2007). Drugs targeting the CXCR4/SDF-1⍺ axis can interrupt the interaction between AML cells and the bone marrow microenvironment. HC4319 is a novel dimeric ligand with high affinity for CXCR4 that was developed by our laboratories to prevent the entry of HIV-1 virus (Xu et al, 2013) and mobilize haematopoietic progenitor cells in animal model (Mao et al, 2018). HC4319 is thought to interrupt the CXCR4/SDF-1⍺ axis interaction and overcome chemoresistance in AML cells. To study the in vitro effect of HC4319 on AML cells, we chose AML cell lines with high expression levels of CXCR4, U937 and HL-60, which were confirmed via flow cytometry after staining them with anti-human CXCR4 antibody (12G5) (Figure S1A). By flow cytometry, we demonstrated that HC4319 binds to both U937 and HL-60 cells in a concentration-dependent manner with a 50% inhibitory concentration (IC50) value of 0·1 µmol/l (Fig 1A), occupying the binding site of 12G5 in the binding pocket of CXCR4 on the cell surface which is part of the SDF-1⍺ binding site (Karpova et al, 2013). To determine the effect of HC4319 on the biological function of AML cells, we performed Transwell assays and found that pre-treatment of U937 and HL-60 cells with HC4319 inhibited their migration induced by SDF-1⍺ in a concentration-dependent manner (Fig 1B) and also inhibited the migration of these cells induced by the co-cultured BMSCs (Figure S1B). The observed cell migration was directly associated with the regulation of cell cytoskeleton rearrangement, with phalloidin-TRITC staining and confocal microscope imaging showing that HC4319 blockage attenuated the polymerization of F-actin and the growth of pseudopods that were promoted by SDF-1⍺ (Figure S1C). Moreover, the immunoblotting assay demonstrated that pre-treatment with HC4319 abrogated the SDF-1⍺-induced phosphorylation of AKT (Ser473) and ERK1/2 (Thr202/Tyr204) in both U937 and HL-60 cells (Fig 1C). These results agree with previous reports that the signalling pathways activated by the SDF-1⍺/CXCR4 axis interaction are involved in activation of PI3K/AKT and MKK-1/ERK1/2 (Ganju et al, 1998). In addition, disruption of the interaction between CXCR4 and SDF-1⍺ has been suggested to be an excellent strategy for attenuating the BMSC-mediated chemoresistance in AML cells, both in vitro and in vivo (Juarez et al, 2003; Zeng et al, 2009). We mimicked the bone marrow microenvironment in vitro by co-culturing BMSCs from femurs and tibias of NSG mice with U937 cells in the presence of cytarabine (Ara-C). In the early stage of apoptosis (at 5 h), BMSCs attenuated the Ara-C-induced increase of Annexin V expression and caspase-3 activity in U937 cells; this attenuation could be prevented by HC4319 pre-treatment (Fig 1D) (Figure S2A). Pre-treatment with HC4319 also decreased the viability of U937 cells that were rescued by BMSCs in the presence of Ara-C (Figure S2B). Importantly, to determine the influence of HC4319 on AML in vivo treatment, especially regarding the mobilization of AML cells and the synergistic effect on AML chemotherapy in vivo, we constructed a previously described AML xenograft mouse model (Matsunaga et al, 2003) by engrafting NSG mice with intravenously injected U937 cells that stably expressed EGFP and luciferase (U937-EGFP/Luc cells). On day 12 after AML cells injection, we collected an equal volume of peripheral blood from the AML xenograft mice before and at different time points after HC4319 administration, isolated the whole white blood cells and stained them with anti-human CD45-PE and 12G5-APC antibodies. Flow cytometry results showed that the mean fluorescent intensity (MFI) of 12G5-staining on the surface of the AML cells sharply decreased at 1 to 3 h and then gradually increased to nearly 50% of the baseline level (before HC4319 administration) at 12 h (Fig 2A). This result indirectly suggested that HC4319 bound to the surface of AML cells when administrated into the AML xenograft mouse and the effect upon this binding peaked at 1 to 3 h, then HC4319 was gradually eliminated from the AML cells surface. Subsequent flow cytometry results also showed that the number of AML cells started to increase from 0·5 h and reached a peak at 3 h, then gradually decreased and almost reached the baseline level at 12 h (Fig 2B). We collected AML xenograft mice femurs and tibias at 3 h after HC4319 administration for immunohistochemical staining with h-CD45; the results showed that much fewer AML cells infiltrated into the bone marrow of mice treated with HC4319 than in the control group (Fig 2C). Therefore, that administration of HC4319 to AML xenograft mice could significantly mobilize AML cells from the bone marrow into the peripheral blood. On day 8, AML xenograft mice were treated with HC4319 in combination with Ara-C, including the relative control as shown in Fig 2D. The bioluminescent imaging showed that the leukaemia burden increased more slowly in the Ara-C monotherapy group than in the control and HC4319 monotherapy groups, but the slowest increase was seen in the HC4319 plus Ara-C group (Fig 2E, F). Meanwhile, HC4319 further prolonged the survival of AML xenograft mice when administrated in combination with Ara-C compared to Ara-C alone, which further confirmed the synergistic effect of HC4319 on AML chemotherapy (Fig 2G). In conclusion, we have clearly demonstrated that the novel dimeric CXCR4 peptide antagonist, HC4319, has a synergistic effect on the treatment of AML when used in combination with Ara-C in a preclinical AML xenograft mouse model via mobilizing AML cells from bone marrow into the peripheral blood and reversing the BMSC-mediated chemoresistance of AML cells. We thank Xiao Fang for providing the parents of NSG mice and Dr. Yinsong Zhu for helping with the animal experiments. Y.H. carried out the experiments and wrote the manuscript. Z.H., J.A. and X.Y. supervised the work and revised the manuscript. The authors declared no potential conflicts of interest. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models

Abstract 7161: Preclinical pharmacology modeling (pharmacokinetics/efficacy) of narazaciclib (HX301 or ON123300) to predict its clinical effective dose

Abstract 5665: HX301 (ON1232580) a novel kinase inhibitor with potent activity against CSF1R and FLT3, shows strong anti-AML activity in defined preclinical models

Abstract 2262: Genomic profiling of leukemic cell lines, responders vs. non-responders to Narazaciclib (HX301 or ON123300), a novel kinase inhibitor with activity against CSF1R and FLT3

STI-8591, a Novel Tyrosine Kinase Inhibitor, Shows Excellent Antileukemic Activity in FLT3-Mutated (mut) Acute Myeloid Leukemia (AML)

ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with <i>FLT3</i>-ITD

A Novel Small Molecule CXCR4 Antagonist Improves Anticancer Therapy by Blocking the Interaction of Malignant Cells with Their Associated Niches

CC-90009, a Novel Cereblon E3 Ligase Modulator, Targets Acute Myeloid Leukemia Blasts and Leukemia Stem Cells.

Elucidating the Mechanism of Action of CC-90009, a Novel Cereblon E3 Ligase Modulator, in AML Via Genome-Wide CRISPR Screen

Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia

Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.

Combination of RSK Inhibitor LJH-685 and FLT3 Inhibitor FF-10101 Promoted Apoptosis and Proliferation Inhibition of AML Cell Lines

LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia

Abstract PO5-24-01: Narazaciclib's differential targets and kinase inhibitory activity contribute to the enhanced inhibition of tumor growth in preclinical models

The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and aurora kinases

SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias

Abstract 5495: PHI-501, a potent and novel inhibitor of NRAS mutated acute myeloid leukemia

Abstract 3229: IACS-16559, a CBP/P300 bromodomain inhibitor for the treatment of specific AML subsets

Abstract 5269: RF-1302, a novel dual inhibitor of PIM1 and FLT3 in preclinical treatment of acute myeloid leukemia

Discovery and Characterization of a Novel Potent Type II Native and Mutant BCR-ABL Inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)

A Novel Dimeric CXCR4 Antagonist Synergizes with Chemotherapy in Acute Myeloid Leukaemia by Mobilizing Leukaemic Cells from Their Associated Bone Marrow Niches